Literature DB >> 12885932

The immune privilege of corneal grafts.

Jerry Y Niederkorn1.   

Abstract

Keratoplasty is the oldest and one of the most successful forms of solid tissue transplantation. In the United States, over 33,000 corneal transplants are performed each year. Unlike other forms of tissue transplantation, keratoplasties are routinely performed without the aid of tissue typing or systemic immunosuppressive drugs. In spite of this, 90% of the first-time corneal transplants will succeed-a condition that demonstrates the immune privilege of keratoplasties. The avascular nature of the corneal allograft bed led many to suspect that corneal grafts were sequestered from the immune apparatus. Although pleasing in its simplicity, this explanation has given way to a more comprehensive hypothesis that embodies multiple, interdependent mechanisms, which promote the long-term survival of corneal allografts. These mechanisms conspire to interrupt the transmission of immunogenic stimuli to peripheral lymphoid tissues; induce the generation of a deviated immune response; and neutralize immune effector elements at the host-graft interface. This paradigm is analogous to a three-legged stool. Disassembly of any one of the three components results in the collapse of immune privilege. Strategies to re-establish corneal immune privilege may have clinical application for high-risk hosts who have rejected previous corneal allografts.

Mesh:

Substances:

Year:  2003        PMID: 12885932     DOI: 10.1189/jlb.1102543

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  45 in total

Review 1.  Graft failure IV. Immunologic mechanisms of corneal transplant rejection.

Authors:  Eva-Marie Chong; M Reza Dana
Journal:  Int Ophthalmol       Date:  2008-06       Impact factor: 2.031

Review 2.  Xenotransplantation--the future of corneal transplantation?

Authors:  Hidetaka Hara; David K C Cooper
Journal:  Cornea       Date:  2011-04       Impact factor: 2.651

Review 3.  Translational Immunoimaging and Neuroimaging Demonstrate Corneal Neuroimmune Crosstalk.

Authors:  Pedram Hamrah; Yashar Seyed-Razavi; Takefumi Yamaguchi
Journal:  Cornea       Date:  2016-11       Impact factor: 2.651

4.  Alloplant implant: a novel biomaterial in the management of recalcitrant glaucoma.

Authors:  Hon-Vu Q Duong; Kenneth C Westfield
Journal:  Medscape J Med       Date:  2008-07-30

5.  IFN-γ blocks CD4+CD25+ Tregs and abolishes immune privilege of minor histocompatibility mismatched corneal allografts.

Authors:  K Cunnusamy; J Y Niederkorn
Journal:  Am J Transplant       Date:  2013-10-01       Impact factor: 8.086

Review 6.  Immune privilege of corneal allografts.

Authors:  Jerry Y Niederkorn; D Frank P Larkin
Journal:  Ocul Immunol Inflamm       Date:  2010-06       Impact factor: 3.070

7.  Reversal of fibrosis by TGF-β3 in a 3D in vitro model.

Authors:  D Karamichos; A E K Hutcheon; J D Zieske
Journal:  Exp Eye Res       Date:  2014-05-04       Impact factor: 3.467

Review 8.  Corneal pain and experimental model development.

Authors:  Tina B McKay; Yashar Seyed-Razavi; Chiara E Ghezzi; Gabriela Dieckmann; Thomas J F Nieland; Dana M Cairns; Rachel E Pollard; Pedram Hamrah; David L Kaplan
Journal:  Prog Retin Eye Res       Date:  2018-11-16       Impact factor: 21.198

9.  VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis.

Authors:  Todd R Wuest; Daniel J J Carr
Journal:  J Exp Med       Date:  2009-12-21       Impact factor: 14.307

10.  Oligopeptide-mediated gene transfer into mouse corneal endothelial cells: expression, design optimization, uptake mechanism and nuclear localization.

Authors:  Wei Yang Seow; Yi-Yan Yang; Andrew J T George
Journal:  Nucleic Acids Res       Date:  2009-08-19       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.